Can Delstrigo treat HIV-1?

What is Delstrigo used for?

Delstrigo is a prescription medication that combines two antiretroviral medications, doravirine and lamivudine, with a fixed-dose combination tablet of emtricitabine and tenofovir disoproxil fumarate in a single tablet [1]. This combination therapy is designed to treat HIV-1 infection in adults [2].

How effective is Delstrigo in treating HIV-1?
Delstrigo has shown efficacy in reducing the level of HIV-1 RNA in the blood in a clinical trial, which is an indicator that the virus is being suppressed [3]. However, more research is needed to confirm its long-term effectiveness and durability in managing the disease.

Key differences in the mechanism of action between Delstrigo and other HIV-1 treatments
Delstrigo works by inhibiting three different targets in the HIV-1 virus, which helps to prevent the virus from replicating [4]. This is different from other HIV-1 treatments that may target only one or two targets. By targeting multiple targets, Delstrigo may be more effective in managing HIV-1 infection.

Is Delstrigo approved by regulatory agencies?
Yes, Delstrigo has been approved by the U.S. Food and Drug Administration (FDA) for use in treating HIV-1 infection in adults [5].

References:
[1] Delstrigo Prescribing Information (2022) - https://www.drugs.com/pro/delstrigo.html
[2] Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate tablets (2022) - https://www.clinicaltrials.gov/ct2/results?term=Delstrigo
[3] ClinicalTrials.gov - Study to Evaluate the Efficacy and Safety of Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate in Participants With HIV-1 (2022) - https://www.clinicaltrials.gov/ct2/show/NCT02285386
[4] HIV Antiretroviral Therapy - Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate (2022) - https://www.drugs.com/hiv/doravirine-lamivudine-tenofovir-disoproxil-fumarate-oral-tablet.html
[5] Delstrigo - FDA Approval History (2022) - https://www.drugs.com/history/delstrigo.html